1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. DESIGN THERAPEUTICS INC

Design Therapeutics Inc XNAS: DSGN

Design Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Download real time

4.65 0.01 (0.22%)

40.15% Fall from 52W High

190.5K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
Durability score
Not Eligible
-
Valuation Score
Expensive Valuation
0.0 / 100
Momentum Score
Technically Bearish
32.3 / 100
Analyst Price Target
No estimates available

10

S

7

W

3

O

1

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Design Therapeutics Inc Live Price Chart

Switch to TradingView
Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2
Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Design Therapeutics Inc Stock Analysis

Design Therapeutics Inc stock analysis with key metrics, changes, and trends.

Design Therapeutics Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Net Profit$49.59 M25.84%positive

Annual Net Profit rose 25.84% in the last year to $49.59 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio-5.32-negative

Price to Earning Ratio is -5.32, which is negative.

Stock Price$4.6542.64%positive

Stock Price rose 42.64% and outperformed its sector by 33.57% in the past year.

Quarterly Net profit$13.65 M15.28%negative

Quarterly Net profit fell 15.28% YoY to $13.65 M. Its sector's average net profit growth YoY for the quarter was -47.3%.

Mutual Fund Holding15.53 %0.28%positive

Mutual Fund Holding increased by 0.28% in the last quarter to 15.53.

Institutional Holding54.60 %2.31%positive

Institutional Holding increased by 2.31% in the last quarter to 54.6.

VIEW LESS


Loading data..

Design Therapeutics Inc - Company Profile

What does Design Therapeutics Inc do?

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Design Therapeutics Inc Management structure

All Gross Remunerations are in USD
Dr. Pratik Shah, PhD
Chairperson of the Board, President, Chief Executive Officer and Principal Financial Officer
-
2024
Gross Remuneration
Year
Ms. Julie Burgess
Chief Accounting Officer
-
2024
Gross Remuneration
Year

Design Therapeutics Inc Board of directors

All Gross Remunerations are in USD
Mr. John P. Schmid
Independent Director
-
2024
Gross Remuneration
Year
Dr. Rodney W. Lappe, PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Pratik Shah, PhD
Chairperson of the Board, President, Chief Executi
-
2024
Gross Remuneration
Year
Dr. Simeon J. George, M.B.A.,M.D.
Lead Independent Director
-
2024
Gross Remuneration
Year
Dr. Heather Berger, PhD
Independent Director
-
2024
Gross Remuneration
Year
Dr. Arsani William, M.D.
Independent Director
-
2024
Gross Remuneration
Year

Design Therapeutics Inc FAQ

How is Design Therapeutics Inc today?
Design Therapeutics Inc today is trading in the green, and is up by 0.22% at 4.65.
Design Therapeutics Inc is currently trading up 0.22% on an intraday basis. In the past week the stock fell -1.06%. stock has been down -25.60% in the past quarter and rose 42.64% in the past year. You can view this in the overview section.